Deerland Probiotics & Enzymes launches new spore-forming strain for immune support
Deerland Probiotics & Enzymes expanded its portfolio of spore-forming probiotics with the launch of MuniSpore.
Photo © Marina_UA - Stock.adobe.com
Deerland Probiotics & Enzymes (Kennesaw, GA) expanded its portfolio of spore-forming probiotics with the launch of MuniSpore, a proprietary strain of Bacillus clausii, for immune support. A soil-based micro-organism,Bacillus clausii CSI08 has been subject to 20 in vitro studies confirming its safety and efficacy. Its effects have been attributed to its ability to positively influence microbial populations and combat oxidative stress. As a spore-forming micro-organism, MuniSpore is also resilient to harsh conditions such as that of the GI tract, as well as wide temperature and pH ranges that makes it ideal for a variety of dosage formats.
“The addition of MuniSpore as an option for formulation allows our customers to address the increased consumer demand for science-backed probiotic products for immune support,” said Sam Michini, Deerland’s vice president of marketing and strategy, in a press release. MuniSpore is generally recognized as safe, and Star-K Kosher certified. Full genome sequencing has also confirmed that the strain is free of plasmids, as well as antibiotic resistant or deleterious genes.
Brightseed launches clinically validated ingredient, Bio Gut Core, to support gut barrier function
May 21st 2025The low-dose, easy-to-formulate ingredient is a proprietary blend of two bioactives – N-trans caffeoyltyramine (NCT) and N-trans feruloyltyramine (NFT) – which were discovered by the company’s Forage AI platform.
A country-by-country blueprint for nutraceutical success in Europe
May 20th 2025The European nutraceutical market is growing rapidly, but the continent is not a monolith when it comes to consumer trends and product innovation. This article is a blue-print for what nutraceutical success looks like in different European countries.
